Drugmaker Merck & Co Inc. revealed on Monday that it is buying a $1 billion equity stake into cancer focused drug developer Seattle Genetic’s common stock. The two companies announced that they would co-develop and sell Seattle Genetics’s cancer therapy, ladiratuzumab vedotin. The two said in a joint statement that they will assess ladiratuzumab vedotin … Continue reading “Merck & Co to Buy $1B Stake in Seattle Genetics”
